抑肽酶在小儿心脏手术中的疗效与安全性:系统综述与荟萃分析
抑肽酶显著减少总失血量、术后输血需求和因出血再手术探查发生率,但增加肾替代治疗风险,对30天死亡率无影响。
要点
- 抑肽酶减少小儿心脏手术总失血量、输血需求及因出血再手术探查。
- 抑肽酶增加肾替代治疗风险,但对30天死亡率无显著影响。
- 新生儿亚组中抑肽酶减少红细胞输注及再手术/填塞发生率。
核心结论
- 荟萃分析提示抑肽酶在小儿心脏手术中有效且耐受良好。
- 鉴于结果异质性大及观察性研究选择偏倚风险,需大型随机对照试验验证。
研究设计与样本
- 系统综述纳入所有比较抑肽酶与氨甲环酸、氨基己酸、安慰剂或无药的随机和观察性研究。
- 检索PubMed、Cochrane Central Register of Controlled Trials、Web of Science和Embase,时间2000年1月至2021年3月。
主要发现
- 抑肽酶显著减少总失血量(平均差-4.70 ml kg-1,95%CI -7.88至-1.53;P=0.004)。
- 抑肽酶减少术后输血需求及因出血再手术探查发生率(OR 0.74,95%CI 0.56至0.97;P=0.03)。
- 抑肽酶对30天死亡率无影响(OR 1.02,95%CI 0.93至1.11;P=0.73)。
- 抑肽酶显著增加肾替代治疗发生率(OR 1.29,95%CI 1.08至1.54;P=0.006)。
- 观察性与随机对照试验结果无大差异;新生儿亚组中抑肽酶显著减少浓缩红细胞输注及术后因出血和/或填塞再手术探查发生率。
关键数值与推荐
- 与赖氨酸类似物相比,抑肽酶在减少出血和输血方面更有效且不增加副作用风险。
临床怎么用
- 小儿心脏手术中可考虑使用抑肽酶以减少失血和输血,但需警惕肾替代治疗风险增加。
局限性
- 结果异质性大。
- 观察性研究存在选择偏倚风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The relicensing of aprotinin in Europe and Canada has stimulated discussions on its usefulness in paediatric cardiac surgery. OBJECTIVE: To systematically evaluate the available evidence on the efficacy and safety of aprotinin in paediatric cardiac surgery. DESIGN: Systematic review of all randomised and observational studies comparing aprotinin with tranexamic acid, epsilon aminocaproic acid, placebo or no drug in paediatric cardiac surgery. Meta-analyses were performed on efficacy and safety outcomes. DATA SOURCES: PubMed, Cochrane Central Register of Controlled Trials, Web of Science and Embase were searched from January 2000 to March 2021. ELIGIBILITY CRITERIA: Studies that enrolled children under 18 years undergoing cardiac surgery with cardiopulmonary bypass. RESULTS: Thirty-two studies enrolling a total of 63 894 paediatric cardiac procedures were included. Aprotinin significantly reduced total blood loss [mean difference -4.70 ml kg-1, 95% confidence interval (CI), -7.88 to -1.53; P = 0.004], postoperative transfusion requirements and the incidence of surgical re-exploration for bleeding [odds ratio (OR) 0.74, 95% CI, 0.56 to 0.97; P = 0.03]. Aprotinin had no effects on 30-day mortality (OR 1.02, 95% CI, 0.93 to 1.11; P = 0.73) and on other safety outcomes, except for the incidence of renal replacement therapy (RRT), which was significantly increased in patients given aprotinin (OR 1.29, 95% CI, 1.08 to 1.54; P = 0.006). Findings from observational and randomised controlled trials did not largely differ. A sub-group analysis in neonates showed that aprotinin significantly reduced packed red blood cell transfusions and the incidence of postoperative surgical re-exploration for bleeding and/or tamponade. When compared with lysine analogues, aprotinin was more effective at reducing bleeding and transfusion without increasing the risk of side effects. CONCLUSION: This meta-analysis suggests that aprotinin is effective and well tolerated in paediatric cardiac surgery. Given the large heterogeneity of the results and the risk of selection bias in observational studies, large randomised controlled trials are warranted.
引用
- Atasever AG, Eerens M, Van den Eynde R, et al. Efficacy and safety of aprotinin in paediatric cardiac surgery: A systematic review and meta-analysis. Eur J Anaesthesiol. 2022. PMID: 34783684. doi:10.1097/EJA.0000000000001632
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。